Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) shares crossed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $24.56 and traded as low as $22.83. Zai Lab shares last traded at $23.47, with a volume of 735,440 shares trading hands.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Citigroup lifted their price target on shares of Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Zai Lab in a research report on Tuesday, October 27th. Wall Street Zen raised shares of Zai Lab from a "sell" rating to a "hold" rating in a research report on Saturday, September 26th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a research note on Tuesday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $37.25.
Read Our Latest Report on Zai Lab
Zai Lab Stock Down 4.6%
The company has a 50 day simple moving average of $24.56 and a 200-day simple moving average of $21.29. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of -13.11 and a beta of 0.77.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.18. The business had revenue of $108.21 million during the quarter, compared to the consensus estimate of $107.90 million. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. On average, equities research analysts expect that Zai Lab Limited Unsponsored ADR will post -2.19 EPS for the current fiscal year.
Insider Buying and Selling
In other Zai Lab news, Director Richard Gaynor acquired 1,228 shares of the firm's stock in a transaction on Tuesday, November 10th. The stock was purchased at an average price of $27.19 per share, with a total value of $33,389.32. Following the completion of the acquisition, the director directly owned 81,965 shares in the company, valued at $2,228,628.35. This trade represents a 1.52% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.88% of the stock is currently owned by corporate insiders.
Institutional Trading of Zai Lab
Institutional investors and hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. purchased a new stake in Zai Lab during the third quarter valued at about $40,643,000. Toronto Dominion Bank acquired a new stake in shares of Zai Lab during the third quarter valued at approximately $26,193,000. Nan Fung Trinity HK Ltd. lifted its position in shares of Zai Lab by 106.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company's stock valued at $7,743,000 after acquiring an additional 151,883 shares in the last quarter. Nantahala Capital Management LLC grew its position in Zai Lab by 65.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company's stock worth $8,692,000 after purchasing an additional 130,000 shares in the last quarter. Finally, Seven Fleet Capital Management LP grew its position in Zai Lab by 74.7% during the 2nd quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company's stock worth $2,584,000 after purchasing an additional 58,158 shares in the last quarter. 41.65% of the stock is owned by institutional investors and hedge funds.
About Zai Lab
(
Get Free Report)
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab's portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.